Outlive: The Science and Art of Longevity: The Million-Copy Bestseller

by Peter Attia

Three of these drugs, known as PI3K inhibitors, have been FDA approved for certain relapsed leukemias and lymphomas, and a fourth was approved in late 2019 for breast cancer.